Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis

Biomarkers

Volumn 14, Issue 1, 2009, Pages 49-54

  Fujimaki, Chihiro ^a   Hayashi, Hideki ^a   Tsuboi, Seiji ^b   Matsuyama, Taiji ^b   Kosuge, Kazuhiro ^a   Yamada, Hiroshi ^a   Inoue, Kazuyuki ^a   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Shizuoka Kousei Hospital   (Japan)

Author keywords

Homocysteine; Inflammation; Methylenetetrahydrofolate reductase; Rheumatoid arthritis; Single nucleotide polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); C REACTIVE PROTEIN; HOMOCYSTEINE; STROMELYSIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PRIMER DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC POLYMORPHISM; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETICS; GENOTYPE; JAPAN; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; JAPAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 66149144789     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902730664     Document Type: Article

References (29)

1. Bellia C, Bivona G, Scazzone C, Ciaccio M. (2007). Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease. Ther Clin Risk Manag 3:999-1001.
2. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, Abou Atta I, Mevorach D, Friedman G, Ben-Yehuda A. (2004). Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227-1231.
3. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. (1998). Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98:2520-2526.
4. Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R. (2003). Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 114:283-287.
5. Dierkes J, Westphal S. (2005). Effect of drugs on homocysteine concentrations. Semin Vasc Med 5:124-139.
6. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. (1999). Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131:363-375.
7. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB. (1999). Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79-84.
8. Inoue S, Hashiguchi M, Chiyoda T, Sunami Y, Tanaka T, Mochizuki M. (2007). Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 8:41-47.
9. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. (1993). Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 88:1463-1469.
10. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. (2002). MTHFR 677C>T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023-2031. (Pubitemid 35204693)
11. Krajinovic M, Moghrabi A. (2004). Pharmacogenetics of methotrexate. Pharmacogenomics 5:819-834.
12. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. (2003). Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593-600.
13. Lazzerini PE, Selvi E, Lorenzini S, Capecchi PL, Ghittoni R, Bisogno S, Catenaccio M, Marcolongo R, Galeazzi M, Laghi-Pasini F. (2006). Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 24:387-393.
14. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, Laghi Pasini F. (2007). Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 6:503-509.
15. Lewis SJ, Ebrahim S, Davey Smith G. (2005). Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ Clin Res ed 331:1053.
16. Martin YN, Salavaggione OE, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM. (2006). Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 16:265-277.
17. Momohara S, Yamanaka H. 2005. [Immunological and serological tests for diagnosis of rheumatoid arthritis: MMP-3]. Nippon Rinsho. Jpn J Clin Med 63 (Suppl. 1):313-317.
18. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. (2003). Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62:4-9. (Pubitemid 36005787)
19. Ranganathan P, McLeod HL. (2006). Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366-1377.
20. Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, Rosenberg IH. (1997). Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 40:718-722.
21. Tso TK, Huang HY, Chang CK, Huang WN. (2006). A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. Clinical Rheumatol 25:285-290.
22. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. (2001). Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195-201.
23. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N. (2002). Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-190.
24. van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, De Boo TM, van de Putte LB. (2002). Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658-665.
25. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, van de Putte LB. (2001). The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-2530.
26. Whittle SL, Hughes RA. (2004). Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43:267-271.
27. Woolf K, Manore MM. (2008). Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. J Am Dietetic Assoc 108:443-453; discussion 454.
28. Yi P, Pogribny I, Jill James S. (2002). Multiplex PCR for simultaneous detection of 677 C>T and 1298 A>C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 181:209.
29. Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapaa-Dahlqvist S. (2003). Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 32:205-210.